Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
j9vC9sLdLJJ30j54
